MOYOM Biotech
China · Healthtech · Biotech
Develops absorbable biomaterials and implantable medical devices for regenerative aesthetic treatments.
Absorbable materials for aesthetic medicine
MOYOM develops materials used in regenerative aesthetic procedures. Its platform combines calcium hydroxylapatite microspheres with a physically cross-linked gel, designed to provide structural support and controlled biodegradation. Aphranel is the commercial brand built on that research.
The company’s September 2026 announcement reports Chinese Class III medical-device registration and European MDR certification for Aphranel. It says the product has entered more than 700 medical-aesthetics clinics in China since its May 2025 launch, placing the business beyond laboratory development and into clinical distribution.
Funding history
1 round · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Financing round | Undisclosed | Cathay Consumer Co-Creation Fund — Role not disclosed |